NEW YORK (GenomeWeb) – Medicare contractor Palmetto GBA issued a draft local coverage determination yesterday stating its plans to stop covering the rheumatoid arthritis test Vectra DA and another draft proposal to extend coverage to Prolaris for patients at intermediate risk for prostate cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.